Evidence method
Level · gp.fundamentals.debt_to_revenue
132.57% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ARQT · Jun 30, 2025
Arcutis Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001787306-25-000124General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.10% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
0.40% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
164.13% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
20.03% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
90.81% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-17.93% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
23.87% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
12.87% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20250/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 163.44%
- Current
- 132.57%
- Delta
- -30.87%
- Previous
- 0.92%
- Current
- 0.10%
- Delta
- -0.83%
- Previous
- -46.14%
- Current
- 0.40%
- Delta
- 46.54%
- Previous
- 32.84%
- Current
- 164.13%
- Delta
- 131.29%
- Previous
- 25.23%
- Current
- 20.03%
- Delta
- -5.20%
- Previous
- 86.59%
- Current
- 90.81%
- Delta
- 4.22%
- Previous
- -37.25%
- Current
- -17.93%
- Delta
- 19.33%
- Previous
- 26.64%
- Current
- 23.87%
- Delta
- -2.77%
- Previous
- 14.85%
- Current
- 12.87%
- Delta
- -1.98%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ARQT Fundamental State →Has State · Arcutis Biotherapeutics, Inc. →Transitioned To · ARQT Fundamental State →Transitioned To · ARQT BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ARQT CAPEX_INTENSITY_DECREASED →Transitioned To · ARQT CASH_GENERATION_INCREASED →Transitioned To · ARQT GROWTH_INCREASED →Transitioned To · ARQT INVENTORY_PRESSURE_DECREASED →Transitioned To · ARQT MARGIN_INCREASED →Transitioned To · ARQT PROFITABILITY_INCREASED →Transitioned To · ARQT R_AND_D_INTENSITY_DECREASED →Transitioned To · ARQT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.